Which strategy is commonly used to convert a 'cold' tumor into a 'hot' tumor?

• A. Monotherapy with PD-1 inhibitors.
• B. Increasing chemotherapy alone.
• C. Combination strategies such as adding CTLA-4 inhibitors or vaccines.
• D. Radiation therapy is avoided.

Answer: (C)

The main idea is that making a cold tumor hot requires driving both the initial T cell activation against the tumor and the subsequent infiltration of those activated cells into the tumor environment. Cold tumors have few tumor-specific T cells and often an immunosuppressive milieu, so you need strategies that boost antigen visibility and T cell priming while also relieving inhibitory signals that prevent those T cells from acting.

Combining approaches like CTLA-4 blockade or vaccines directly addresses this. CTLA-4 inhibitors release brakes on early T cell activation and expansion in lymphoid tissues, helping generate more tumor-specific T cells. Vaccines provide the immune system with the right targets to recognize, priming T cells to attack tumor cells. When these tactics are paired with other immunotherapies, they can create a more inflamed tumor microenvironment with increased T cell infiltration and activity, effectively turning a non-inflamed (“cold”) tumor into an inflamed (“hot”) one that’s more responsive to immune attack.

Single-agent PD-1 inhibitors often struggle in cold tumors because there aren’t enough active T cells to reinvigorate. Increasing chemotherapy alone isn’t reliably sufficient to spark durable anti-tumor immunity. Radiation can also help prime immunity, but the question focuses on combination strategies that actively promote T cell priming and activation, which is why combining CTLA-4 blockade or vaccines with other immune-modulating approaches is the best fit.